VEGFA and neoplasm: In addition, bevacizumab (monoclonal antibody specific for VEGF) in combination with chemotherapy, the current standard of care therapy for metastatic colorectal cancer results in tumor hypoxia, which drives extracellular matrix (ECM) remodeling involved in acquired therapy resistance [15].